Matrix metalloproteinases (MMPs) function in the remodeling of the extracellular matrix that is integral for many normal and pathological processes. The tissue inhibitor of metalloproteinases family, including tissue inhibitor of metalloproteinases-2 (TIMP-2), regulates the activity of these multifunctional metalloproteinases. TIMP family members are proteinase inhibitors that contain six conserved disulfide bonds, one involving an amino-terminal cysteine residue that is critical for MMP inhibitor activity. TIMP-2 has been expressed in Escherichia coli, folded from insoluble protein, and functionally characterized. The wild type protein inhibited gelatinase A (MMP-2), whereas a variant with an alanine appended to the amino terminus (Ala؉TIMP-2) was inactive. Removal of amino-terminal alanine by exopeptidase digestion restored protease inhibitor activity. This confirms the mechanistic importance of the amino-terminal amino group in the metalloproteinase inhibitory activity, as originally suggested from the x-ray structure of a complex of MMP-3 with TIMP-1 and a complex of TIMP-2 with MT-1-MMP. The Ala؉TIMP-2 variant exhibited conformational, pro-MMP-2 complex formation and fibroblast growth modulating properties of the wild type protein. These findings demonstrate that Ala؉TIMP-2 is an excellent biochemical tool for examining the specific role of MMP inhibition in the multiple functions ascribed to TIMPs.
Studies of disease states, such as arthritis and tumor progression, have demonstrated that the matrix metalloproteinases (MMPs) 1 and their inhibitors, the tissue inhibitors of metalloproteinases (TIMPs), are critical effectors of extracellular matrix turnover. In recent years, the role of MMPs and TIMPs in a variety of pathologic entities has greatly expanded. This suggests that therapeutic targeting of these proteases may be beneficial not only in cancer and arthritis but also in a wide spectrum of pathologic conditions, ranging from rather common pathologic entities, such as nonhealing wounds (e.g. decubitus ulcers), to rare conditions such as pulmonary lymphangiomyomatosis (1, 2) . Although current attempts to modulate MMP activities are based principally on substrate analog approaches, an alternative strategy is to utilize analogs of the endogenous inhibitors, the TIMPs.
The TIMPs form a family of at least four members, the best characterized of which are TIMP-1 and -2 (2, 3). TIMP-2 (21 kDa) is a nonglycosylated protein that shares a 66% sequence identity with the glycosylated TIMP-1 (28.5 kDa); each protein contains 12 conserved cysteine residues that form six disulfide bonds essential for maintaining functional and structural integrity. The initial stage of TIMP inhibition of MMPs involves the formation of binary complexes. The amino-terminal cysteine appears to play a key role in blocking catalytic activity. The crystal structure of an MMP-TIMP-1 complex between the catalytic domain of stromelysin-1 (MMP-3) and human TIMP-1 showed that Cys-1 bidentally coordinates the active site zinc atom, and the Thr-2 side chain extends into the large specificity pocket of MMP-3 (4) . In proteins, amino-terminal disulfide bonded cysteine residues are rare, yet the amino-terminal Cys-1 residue of TIMPs appears to be the critical residue responsible for inhibition of MMP activity (4) . To functionally test this hypothesis, we have prepared a TIMP-2 mutant that contains a single alanine appended to the amino-terminal cysteine residue; we refer to this mutant as AlaϩTIMP-2. TIMP-2 was expressed in Escherichia coli in its mature form (lacking the signal sequence) with either Met or Met-Ala at the amino terminus. The present report demonstrates both that constructs can be correctly refolded and that the AlaϩTIMP-2 is devoid of MMP-2 inhibitory activity but that this activity can be recovered following treatment with an exopeptidase to remove the amino-terminal Ala-residue.
TIMP-2 can bind to the pro-form of gelatinase A (pro-MMP-2). This specific binding appears to be mediated by the carboxyl-terminal domains of each protein (5) (6) (7) . In this study, we also show that this binding is independent of MMP-2 inhibitory activity, as inactive AlaϩTIMP-2 forms a tight binary complex with pro-MMP-2. This also allowed an independent assessment of conformational integrity of AlaϩTIMP-2, at least for the carboxyl-terminal domain. Finally, we demonstrate that, like * The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
¶ To whom correspondence should be addressed: ECMPS, Laboratory of Pathology, NCI, National Institutes of Health, Bldg. 10 wt TIMP-2, AlaϩTIMP-2 induces a mitogenic response in serum-starved quiescent fibroblast (synchronized) and modulates the mitogenic response of these cells to basic fibroblast growth factor (bFGF). These findings demonstrate that amino-terminal blocked TIMPs are useful biochemical tools in that they can mediate functional dissection of the multiple roles that these important protease inhibitors may play in tissue remodeling.
EXPERIMENTAL PROCEDURES
Construction of Expression Plasmids-Two different forms of TIMP-2 protein were produced in E. coli using plasmid pET11a and host bacterial strain BL21(DE3) as described by Studier et al. (8) . TIMP-2 was expressed in its mature form (lacking the signal sequence) with either a Met or Met-Ala at the amino terminus. The TIMP-2 portion of the protein extends from Cys-1 to Pro-193. The DNA encoding TIMP-2 was prepared as a NdeI-BglII fragment using polymerase chain reaction as described by Scharf et al. (9) , using pTIMP-2 (MO1) (10) as the template, inserted between the NdeI and BamHI restriction sites of pET11a.
Expression and Purification of TIMP-2-Plasmid DNAs were transformed into E. coli strain BL21 (DE3) (8) . Fermentations were in a MD2 2-liter benchtop fermentor (Braun Biotech Inc.) as described previously (11) . Fermentation yielded about 50 g wet weight of cells, which were stored at Ϫ80°C until needed for processing. Proteins were expressed as insoluble inclusion bodies, which were solubilized with 8 M guanidine hydrochloride (Gdn-HCl) and then subjected to gel filtration chromatography in the presence of 4 M Gdn-HCl as described previously (11) . To the pool of partially purified protein (ϳ500 -600 mg), solid Gdn-HCl was added, raising its concentration from 4 to 6 M, and fresh dithiothreitol was added to 10 mM. The solution was concentrated to ϳ20 mg/ml using a stirred cell with a Diaflo PM-10 ultrafiltration membrane (Millipore-Amicon), aliquoted and stored at Ϫ80°C. Protein folding was carried out on 100-mg batches by slowly adding the protein (5 ml) over several hours to a 1-liter stirred solution of 100 mM Tris-HCl, pH 8.0, containing 2.5 M urea, 5 mM reduced glutathione, 1 mM oxidized glutathione, 1 mM EDTA, and 0.1 mM 4-(2-aminoethyl)benzenesulfonyl fluoride. The mixture was gently stirred for 24 h and then dialyzed: first, against 5 liters of 50 mM Tris-HCl, pH 8.0, for 10 -12 h and then for a further 10 -12 h against 15 liters of the same buffer. All dialysis stages were carried out at 4°C. The protein was concentrated to about 5 ml, filtered using 0.22 m Millex-GV filter units (Millipore), and applied to a column 2.6 cm in diameter ϫ 60 cm of Superdex 75 equilibrated in 50 mM Tris-HCl, pH 8.0, containing 100 mM NaCl. Column fractions following pretreatment with 10 mM iodoacetamide were assayed by SDS-PAGE under nonreducing conditions. Monomeric protein was pooled from the main peak, which was well separated from aggregated and dimeric (disulfide cross-linked) protein. The overall recovery of folded protein was between 15-20% (15-20 mg) .
Other Recombinant Produced Proteins-TIMP-2 and progelatinase A (pro-MMP-2) were expressed in vaccinia virus expression systems and were purified as described previously (12) .
Determination of Protein Concentration-Purified TIMP-2 proteins were quantified by measuring their absorbance at 280 nm in a 1-cmpath length cell using a double-beam, diode-array Hewlett-Packard 8450A UV/VIS spectrophotometer. The extinction coefficient (⑀ mg/ml ) used was 1.47 and was calculated from the amino acid composition of wild type protein according to Wetlaufer (13) .
Protein Sequencing-Samples were applied to polyvinylidene difluoride membranes using the ProSpin preparation cartridge (PerkinElmer Corp.). Automated Edman degradation was performed using the Blott Cartridge and an Applied Biosystems model 477A protein sequencer (Perkin-Elmer).
Analytical Ultracentrifugation-Analytical ultracentrifugation was performed using a Beckman Optima XL-I analytical ultracentrifuge with an An-60 Ti rotor and standard double-sector centerpiece cells. For equilibrium measurements, samples (100 l) were centrifuged at 20°C and 21,500 rpm (TIMP-2) or at 10°C and 12,000 rpm (TIMP-2-pro-MMP-2). Absorbance data was collected for 16 h, and then baseline corrections were established by overspeeding for 4 h at 40,000 rpm. Protein partial specific volumes were calculated from the amino acid composition (14) and solvent densities were calculated as described by Laue et al. (15) .
Circular Dichroism and Fluorescence Measurements-CD spectra were recorded on a Jasco J-720 spectropolarimeter. Measurements in the near-(360 -240 nm) and far-(260 -180 nm) (UV) regions were made using 1-and 0.02-cm-path length cells, respectively. A 1 nm bandwidth was used for both spectral regions. Protein solutions were 0.75-1 mg/ml in 50 mM sodium phosphate, pH 7.5. Protein buffers were exchanged using Sephadex G-25 M (PD-10 columns, Amersham Pharmacia Biotech). Immediately prior to use, solutions were filtered with 0.22 m pore size Millex-GV filter units and briefly degassed. Fluorescence measurements were carried out using a Perkin-Elmer LS-50B luminescence spectrometer. The excitation wavelength was 295 nm and both the excitation and emission bandwidths were 2.5 nm. Spectra were recorded at 22°C. Further details are found in the legend to Fig. 2 .
Binding of TIMP-2 to Pro-MMP-2-Pro-MMP-2 (1 ml at 0.34 mg/ml) was incubated for 1 h at 4°C with a 5-fold molar excess of AlaϩTIMP-2 (0.5 ml at 0.5 mg/ml). The mixture was applied to a Superdex 200 column 1.6 ϫ 60 cm equilibrated with 50 mM Tris-HCl, pH 7.5, 200 mM NaCl, 5 mM CaCl 2 , and 5 mM CHAPS. The column was eluted at 2 ml/min at 5°C. Fractions corresponding to the two major peaks were pooled, concentrated and then dialyzed against column buffer containing 2 mM CHAPS and 1 mM CaCl 2 The composition of column fractions was determined by SDS-PAGE and gel densitometry. The molecular weight of the native complex was determined by sedimentation equilibrium.
Exopeptidase Digestion of AlaϩTIMP-2-Aminopeptidase I (Sigma) was reconstituted to give a stock concentration of 0.5 mg/ml in 50 mM Tris-HCl, pH 7.5, and stored at Ϫ80°C. Stock solutions were diluted 100-fold to prepare working solutions. Purified, recombinant AlaϩTIMP-2 was digested with aminopeptidase I (Sigma) at 37°C at 1:5 (w/w) or 1:100 (w/w) enzyme:substrate ratio in a final volume of 0.176 ml. Aliquots of this reaction mixture of digested AlaϩTIMP-2 were removed at the time points indicated in Fig. 4 . The aliquots were diluted and analyzed for MMP inhibitor activity using the thiopeptolide assay (1:5 (w/w) enzyme:substrate) and reverse zymography (1:100 (w/w) enzyme:substrate), as described previously (16, 17) .
Kinetic Analysis-Inhibitor activities of recombinant TIMP-2 and AlaϩTIMP-2 were assayed against recombinant human MMP-2. The pro-MMP-2 was activated using 1 mM para-aminophenylmercuric acetate (pAPMA, Sigma) at 37°C for 30 min. Activated protease was diluted then assayed utilizing the thiopeptolide, Ac-Pro-Leu-Gly-thioester-Leu-Leu-Gly-OEt (Bachem Bioscience, King of Prussia, PA), as described previously (16) . In assays to determine the inhibitor constants for TIMP-2 and AlaϩTIMP-2, the thiopeptolide concentration was 300 M, the final concentration of activated MMP-2 was 0.53 nM, and the recombinant TIMP-2 preparations ranged from 0.24 to 2.4 nM. A typical reaction time course was measured for 2 h on 96-well plate with absorbance changes monitored at 405 nm using a THERMOmax microplate reader at room temperature. The inhibitory constant K i for the tight-binding forms of TIMP-2 was calculated according to the method of Henderson (18) , which accounts for systems in which a substantial fraction of the inhibitor is bound. Data were analyzed by linear regression for determination of K i values.
Thiopeptolide assays were also performed on aliquots of the aminopeptidase I digestion of AlaϩTIMP-2 removed at the various time points. The final concentration of active MMP-2 in these assays was 18.2 nM. To optimize sensitivity for detection of TIMP inhibition the total TIMP-2 concentration, AlaϩTIMP-2 plus exopeptidase processed AlaϩTIMP-2, ranged up to 180 nM. Data were plotted as initial velocity of MMP-2 activity versus the time of exopeptidase digestion and analyzed by linear regression analysis.
Reverse Zymogram Analysis-AlaϩTIMP-2 samples from the aminopeptidase I digestion were diluted with 5ϫ SDS sample buffer without 2-mercaptoethanol and analyzed by reverse zymography as described previously (17), utilizing both wt TIMP-2 and undigested AlaϩTIMP-2 as controls. Reverse zymograms were quantitated by scanning the gels and optical integration of the band densities using the NIH Image program as described (17) . Aliquots (40 l) of the aminopeptidase digest samples containing 12 g of digested AlaϩTIMP-2 were also electrophoresed on a 4 -20% acrylamide gradient gel following reduction with 2-mercaptoethanol and heating at 95°C for 2 min. Following electrophoresis, the gels were silver stained (Daiichi 2D Silver Stain II, Daiichi Pure Chemicals Co., Ltd.). The silver-stained gel was used as a loading control to ensure that all wells in the reverse zymogram contained equivalent amounts of recombinant AlaϩTIMP-2 starting material and that contaminating endopeptidase activity did not degrade AlaϩTIMP-2. Undigested AlaϩTIMP-2 as well as wt TIMP-2 were included as control. The loading of wt TIMP-2 on reverse zymogram corresponds to 12 ng of total protein in accordance with the previously reported sensitivity for reverse zymogram analysis (17) .
Fibroblast Cell Culture Conditions-Human dermal fibroblast Hs68 cells were used from passages 14 -24. Cells were grown in DMEM containing 10% fetal calf serum until 80% confluent. The cells were subsequently trypsinized, counted, and incubated on 96-well plates (Costar) at 5 ϫ 10 3 cells/well and allowed to recover overnight in 100 l of DMEM with 10% fetal calf serum. This recovery was followed by 24 h incubation in serum-free DMEM to allow cells to quiesce and synchronize. Prior to treatment with AlaϩTIMP-2 or stimulation with bFGF, the cells were washed once with 100 l of serum-free DMEM.
[ 3 H]Thymidine Incorporation Assays-Hs68 cells were starved and washed with 100 l of serum-free DMEM prior to treatment as described above. AlaϩTIMP-2 was preincubated with the cells for 30 min or added just prior to growth factor stimulation. Following growth factor addition, the cells were then allowed to incubate 18 h. [ 3 H]Thymidine (Amersham Pharmacia Biotech; 40 Ci/ml) was then added to the cells and incubated for 2 h at 37°C. After the thymidine pulse, unincorporated thymidine was discarded by a phosphate-buffered saline wash, and the cells were fixed using methanol:acetic acid (3:1). The thymidine was extracted using trypsin (Life Technologies, Inc.) and SDS as described previously (19, 20) . Statistical significance was determined using the Student t test (Statview program).
RESULTS
Protein Expression and Purification-TIMP-2 was either expressed in E. coli with the authentic sequence (wt) or with an alanine residue appended to the amino-terminal cysteine (AlaϩTIMP-2). Both constructs formed insoluble inclusion bodies, which were partially purified by gel filtration in Gdn-HCl, folded and oxidized using a simple dilution-dialysis scheme, and then purified further by gel filtration under native conditions. This approach has been successfully applied to other insoluble and difficult to handle E. coli-expressed proteins (11, 21) . From 1 liter of cell culture (ϳ50 g wet weight), over 100 mg of pure TIMP-2 can be recovered from either of the constructs.
Protein Characterization-Previous characterization of wt TIMP-2 produced in the vaccinia expression system demonstrated that these preparations retain full MMP inhibitor activity and have been utilized to characterize the carboxyl-terminal domain interactions with MMP-2 (6, 12) . For this reason we have utilized vaccinia-produced wt TIMP-2 as a standard for comparison in characterization of E. coli-produced recombinant wt TIMP-2 and AlaϩTIMP-2.
Amino-terminal sequencing of AlaϩTIMP-2 indicated a single amino terminus with the predicted sequence, ACSCSP. On the other hand, protein derived from the authentic sequence construct (wt) exhibited both retention of methionine from the initiating N-formyl-methionine and amino-terminal processing. Three sequences were thus observed, and their relative abundance was as follows: MCSCSP, 20%; CSCSP, 70%; and SCSP, 10%. We have previously seen ragged N termini with other unrelated proteins containing amino-terminal cysteine. 2 SDS-PAGE of the purified proteins is shown in Fig. 1 . The apparent molecular mass of all the various recombinant TIMP-2 under reducing conditions was about 28 kDa, somewhat higher than predicted from the DNA coding sequence (ϳ22 kDa). Under nonreducing conditions, the apparent molecular masses were significantly lower (ϳ22 kDa), indicating more compact structures due to disulfide cross-linking. It could be seen that the E. coli-produced and vaccinia-generated TIMP-2 have very similar mobilities under both reducing and nonreducing conditions. It is also apparent that for the E. coli wt TIMP-2 construct that under nonreducing conditions there is a small amount of disulfide cross-linked dimer (Fig. 1, lane  d) . This presumably originates from protein containing an unpaired cysteine (ϳ10%) due to processing of the amino-terminal cysteine that normally forms one of the six intramolecular disulfides in TIMP-2.
The molecular masses of the proteins were measured under native conditions by sedimentation equilibrium. The vacciniaproduced protein behaved as an ideal monomer over the concentration range studied (0.1-2.0 mg/ml), with a determined molecular weight of 22,250 (compared with 21,826 predicted from the DNA coding sequence). The E. coli AlaϩTIMP-2 was also a well behaved monomer (M r ϭ 23,000), whereas the E. coli wt TIMP-2 construct contained 5-10% dimer, consistent with the SDS-PAGE results discussed above.
Conformational Analysis-Far UV CD spectra of the E. coliand vaccinia-derived TIMP-2 proteins are shown in Fig. 2A . Again, in these structural comparisons, we have utilized the previously well characterized vaccinia-derived TIMP-2 as the standard for comparison. At wavelengths above 200 nm, the spectra of the three proteins are identical. Below 200 nm, the spectra are also very similar in general terms of the peak positions with slight variations in intensities of mean residue ellipticity. This indicates that all three proteins have similar overall secondary structures. Secondary structures were estimated from these spectra using three methods (22) (23) (24) , all of which gave similar results: 14% ␣-helix, 44% ␤-sheet, and 42% other. These solution values are similar to the secondary structure content (17% ␣-helix and 30% ␤-sheet) derived from the recently determined x-ray structure of TIMP-2 in complex with the catalytic domain of MT-1-MMP (25) .
The tertiary fold of the proteins was assessed by near-UV CD and fluorescence emission spectroscopy; both measurements are sensitive probes of tertiary conformation (26) . The similarity of the spectral CD fingerprints of the active vaccinia and inactive AlaϩTIMP-2 proteins indicates that the overall conformation of these proteins is similar (Fig. 2B) (the E. coli wt TIMP-2 also has similar spectral properties, data not shown). Denaturation and reduction of the proteins using 4 M Gdn-HCl and 10 mM dithiothreitol eliminates the prominent CD bands, showing that they were derived from folded protein (Fig. 2B) . The fluorescent emission spectra of the vaccinia and AlaϩTIMP-2 proteins are also very similar, again suggesting similar tertiary structures (Fig. 2C) (data for E. coli wt TIMP-2 not shown). The spectra are somewhat red-shifted with peak maxima ( max) at about 344 -346 nm. According to the classification of Burstien et al. (27) , TIMP-2 is a class II protein ( max 340 -342 nm), implying that the average Trp content is partially solvent exposed (compare with a max of 350 -355 nm for fully exposed Trp in denatured protein). Again, this is consistent with the TIMP-2 x-ray structure (25) , in which only Trp-148 appears solvent inaccessible; the other three Trps all exhibit varying degrees of exposure, especially the carboxylterminal Trp-177.
Kinetic Analysis of MMP Inhibitor Activity-The inhibitory activity of the E. coli wt TIMP-2, AlaϩTIMP and mammalian cell-produced TIMP-2 from vaccinia was determined utilizing a modification of the coupled assay system containing a thiopeptolide substrate previously described (16) . The K i values for the vaccinia virus-produced TIMP-2 (0.7 Ϯ 0.3 nM) and E. coli wt TIMP-2 (0.6 Ϯ 0.3 nM) are essentially identical. These values are similar to those determined by kinetic analysis of TIMP-1 inhibition of MMP-2 reported previously (28), as well as apparent K i values for the TIMP-2 inhibition of MMP-2 reported by Murphy and colleagues (7). The K i value (24 Ϯ 2 M) for AlaϩTIMP-2 on the other hand was quite large representing a decrease in over four orders of magnitude over the wild type protein, indicating that this substituted TIMP-2 has little MMP inhibitory activity. Similar changes in the K i values for TIMP-1 mutants have been previously observed for amino acid substitutions that result in significant disruption of the protein secondary and tertiary structure, as evidenced by changes in the near UV CD spectra (28) . Conformational change is unlikely to be the reason for the inactivity of the AlaϩTIMP-2 variant as described above; this variant has the same secondary and tertiary structure as active wt TIMP-2 produced in E. coli or vaccinia.
Binding of E. coli AlaϩTIMP-2 to Pro-MMP-2-The inhibition of MMPs by
TIMPs is accompanied by the formation of tight binary complexes involving mainly the carboxyl-terminal domains of both proteins (Ref. 25 and references therein). As high affinity protein-protein interactions are conformation-dependent, we examined the binding of AlaϩTIMP-2 to pro-MMP-2. A mixture of these proteins was subjected to gel filtration (Fig. 3A) . Densitometry of SDS-PAGE separated protein in peak 1 (Fig. 3B) , indicated progelatinase A and AlaϩTIMP-2 present in a 1:0.90 molar ratio. The molecular weight of the complex under native conditions was directly determined by sedimentation equilibrium analysis. As there was no evidence for association or dissociation of the complex during gel filtration (a symmetrical, nontrailing peak), the equilibrium data was modeled as a single species. A molecular weight of 90,000 was determined for the protein in peak 1, consistent with the formation of an equimolar complex (predicted combined mass of 92.8 kDa). These results are consistent with the correct folding of the AlaϩTIMP-2 protein that preserves the ability of this protein to interact with pro-MMP-2 in a highly specific fashion.
Aminopeptidase I Treatment of AlaϩTIMP-2 Recovers MMP Inhibitor Activity-To show that the inactivity of AlaϩTIMP-2 was solely due to the blocking of the cysteine amino terminus, we subjected the protein to aminopeptidase I digestion. The digests were then assayed in both the thiopeptolide and reverse zymogram analysis to test for the recovery of MMP inhibitory activity.
The results of the thiopeptolide assay, shown in Fig. 4A , demonstrate that there is a time-dependent recovery of MMP-2 inhibitor activity in the aminopeptidase I digestion of AlaϩTIMP-2. The initial mean velocity of the MMP-2-mediated thiopeptolide hydrolysis treated with aminopeptidase I-digested AlaϩTIMP-2 (182 nM total TIMP-2) decreased from 14.9 Ϯ 0.29 milli-absorbance units min Ϫ1 at the zero time point to 11.1 Ϯ 0.29 by the 300-min time point of the endopeptidase treatment. For comparative purposes, the level of MMP-2 activity in the absence of added TIMP-2 ranged from 14.3 to 15.4 milli-absorbance units min Ϫ1 , and the mean value for the reaction containing 18.5 nM wt TIMP-2 was 9.88 Ϯ 0.50 milliabsorbance units min Ϫ1 . These data suggest that by the last time point assayed in this aminopeptidase I digestion of AlaϩTIMP-2, there is approximately 10% removal of the amino-terminal appended Ala residue under these assay conditions.
The recovery of MMP inhibitor activity following aminopeptidase treatment was confirmed by reverse zymogram analysis. Fig. 4B demonstrates a progressive, time-dependent increase in MMP inhibition evidenced by the increase in band intensity of the 21 kDa TIMP-2 band (Fig. 4B, upper panel) . In addition, silver staining of heavily overloaded samples (Fig. 4B, lower  panel) demonstrates that the AlaϩTIMP-2 digests are equally loaded in all lanes and that the AlaϩTIMP-2 is not degraded by contaminating endopeptidase activity in the aminopeptidase I preparations.
The reverse zymogram analysis is highly sensitive and quantitative. In these reactions, we could demonstrate effective removal of the amino-terminal appended Ala-residue and recovery of MMP inhibitor activity as early as 45 min following exposure to aminopeptidase I. Fig. 4C represents the integrated mean pixel intensity for the data presented in Fig. 4B , upper panel. The data again demonstrate a time-dependent increase in the recovery of MMP inhibitor following aminopeptidase I treatment of AlaϩTIMP-2 that is first detectable at 45 min. In this experiment the level of recovered MMP inhibitor activity at the 150 and 240 min time points exceeded the levels observed in the wt TIMP-2 (12 ng) used as a positive control (integrated density, 196 relative units). These findings suggest that reverse zymography is more sensitive in detecting the processed AlaϩTIMP-2 than the solution based thiopeptolide based assay. This may in part be due to the restricted diffusion and limited amounts of metalloproteinase available in the reverse zymogram analysis. In separate experiments, we observed greater than 95% removal of the amino-terminal appended Ala residue as determined by direct amino acid sequencing (data not shown). This suggest that aminopeptidase I treatment of AlaϩTIMP-2 could be used to effectively recover fully functional wt TIMP-2 from AlaϩTIMP-2 preparations. In summary, the results of both the thiopeptolide assay   FIG. 4 . Aminopeptidase I digestion of Ala؉TIMP-2. AlaϩTIMP-2 was incubated aminopeptidase I as described under "Experimental Procedures." Aliquots were removed at the indicated times (in min) and subjected to assays for detection of MMP-2 inhibitor activity by thiopeptolide assay or reverse zymography. A, thiopeptolide assay demonstrating recovery of MMP-2 inhibitor activity following treatment of AlaϩTIMP-2 with aminopeptidase I. Purified, recombinant AlaϩTIMP-2 was incubated with aminopeptidase I (1:5 (w/w) enzyme: substrate ratio) as described under "Experimental Procedures." Aliqouts of this digest were removed at the indicated time points and diluted and assayed for inhibitor activity against 18.2 nM activated MMP-2. OE, aliquots from aminopeptidase I digestion of AlaϩTIMP-2; f, wt TIMP-2 inhibition of MMP-2; Ⅺ, control reaction with no added TIMP-2 or AlaϩTIMP-2 digest. B, reverse zymogram analysis aminopeptidase I digestion of AlaϩTIMP-2. Purified, recombinant AlaϩTIMP-2 was incubated with aminopeptidase I (1:100 (w/w) enzyme:substrate ratio) as described under "Experimental Procedures." Aliquots were removed at the indicated time points and subjected to reverse zymogram analysis (upper panel) and SDS gel electrophoresis (lower panel). Untreated AlaϩTIMP-2 and wt-TIMP are included as controls. The results demonstrate increased MMP inhibitor activity with time of aminopeptidase I incubation. Removal of the Ala residue appended to the amino-terminal cysteine of the wt TIMP-2 was confirmed in independent experiments by direct amino acid sequencing (see text). C, quantitation of reverse zymogram analysis. Reverse zymogram was scanned using a Agfa flat-bed scanner as an 8-channel gray scale image into Adobe Photoshop. The TIFF file was then imported into NIH Image software for quantitation as described (17) .
The data demonstrate a time-dependent increase in MMP inhibitor activity as indicated by a increase in the integrated absorbance of the 21-kDa band associated with TIMP-2.
and reverse zymogram demonstrate that removal of the aminoterminal Ala residue from the AlaϩTIMP-2 result in recovery of MMP inhibitor activity. These findings confirm that AlaϩTIMP-2 is correctly folded and that loss of MMP inhibitor activity is solely due to the amino terminus appended Al-residue.
AlaϩTIMP-2 Modulation of Human Dermal Fibroblast Growth-Previously, our laboratory has reported that TIMP-2 can stimulate the growth of serum-starved, quiescent fibroblasts (19) and suppresses the bFGF-mediated proliferation of human microvascular endothelial cells (20) . In the present report, we have investigated AlaϩTIMP-2 modulation of normal fibroblast growth. Consistent with our previous observations using wt TIMP-2 treatment of human fibroblasts (19) , treatment with either wt TIMP-2 or AlaϩTIMP-2 alone stimulates the proliferation of quiescent fibroblasts (Table I) . However, preincubation of AlaϩTIMP-2 (24 nM) for 30 min or immediately prior (1 min preincubation) to treatment with bFGF (50 ng/ml) decreased the maximal bFGF proliferative response to a level comparable to TIMP-2 treatment alone (Table I) ; similar results were obtained with wt TIMP-2 (data not shown). If AlaϩTIMP-2 was added 30 min after treatment with bFGF, the suppression of proliferation was not observed (Table  I) . Inhibition of bFGF proliferation by AlaϩTIMP-2 was evident as early as 6 h after treatment with bFGF and became more pronounced 24 h after bFGF stimulation (data not shown). These results demonstrate that, like wt TIMP-2, AlaϩTIMP-2 modulates the fibroblast growth response and that AlaϩTIMP-2 retains equipotent growth modulating activity as that previously reported for wt TIMP-2. Previous studies have demonstrated that modulation of fibroblast growth responses were unique to TIMP-2 and were not observed using TIMP-1 and/or synthetic MMP inhibitors (Batimastat, BB-94), suggesting that these activities were independent of MMP inhibitor activity. The present study using AlaϩTIMP-2 devoid of MMP inhibitor activity confirms that the growth modulating properties described here are independent of TIMP-2 ability to inhibit MMP activity.
DISCUSSION
Our report is the first to document production and functional characterization of an active full-length TIMP-2 protein expressed in E. coli. Most reports to date have utilized mammalian expression systems (e.g. vaccinia virus, Chinese hamster ovary cells, etc.) that obviate the need for refolding of isolated protein. The advantages of E. coli expression for the production of TIMP-2 are ease of production, high yield, and ability to label protein with stable isotopes for high resolution NMR. TIMP-2 protein preparations produced in this E. coli system and refolded in vitro are well defined monomers that are well suited for structural and functional studies. Conformational analysis of the wt TIMP-2 and AlaϩTIMP-2 produced in E. coli and comparison with that produced in mammalian expression system (e.g. vaccinia virus) demonstrates that there are no significant differences (Fig. 2) . One advantage of the production of the AlaϩTIMP-2 protein is that it is not susceptible to aminoterminal processing and may therefore be better suited for structural work.
Our report is also the first to functionally demonstrate that TIMP-2 is only active in inhibiting MMP activity when the amino-terminal amino group of the Cys-1 residue is free. This finding is confirmation of the mechanism involving the amino group of Cys-1 that was first suggested by the x-ray structure of TIMP-1/MMP-3 catalytic domain complex (4). This concept is now definitively demonstrated using the Alaϩ construct in which there is essentially complete loss of MMP inhibitory activity without disruption of the protein structure. The essentially total lack of MMP inhibition by the AlaϩTIMP-2 mutant suggest that coordination of the zinc atom by the free amino group of Cys-1 is an important interaction is stabilizing TIMP-2 binding to the MMP active site. The addition of a single Ala residue onto the amino terminus is sufficient to disrupt secondary interactions that might otherwise stabilize TIMP-2 interaction with the MMP active site. Alternatively, the Ala residue appended to the amino terminus may result in a subtle alteration in the TIMP-2 structure that precludes binding to the active site. Resolution of this issue will await x-ray or NMR analysis of the AlaϩTIMP-2 structure.
Although the Alaϩ construct is inactive in blocking MMP activity, the protein appears to have a similar overall secondary (far-UV CD data) and tertiary structure (near-UV CD and fluorescence emission) as either mammalian (vaccinia virusproduced) or E. coli proteins with the authentic amino terminus (wt). Furthermore, the functional nature of the protein is demonstrated by the retention of complex formation with pro-MMP-2 and the recovery of MMP inhibitory activity following removal of the amino-terminal Ala residue by treatment with aminopeptidase. The assay conditions utilized to demonstrate recovery of MMP inhibitor activity in the thiopeptolide assay following treatment of AlaϩTIMP-2 with aminopeptidase resulted in recovery of 10% of maximal activity at the 300-min time point (Fig. 4A) . The slow rate of recovery of MMP inhibitor activity observed in the functional assays (both thiopeptolide and reverse zymograms) reflects low efficiency of the aminopeptidase I in cleaving Ala-Cys bond. This low yield is likely due to the fact that the Cys-1 residue is disulfide bonded to the Cys-72 residue, and the accessibility of the aminopeptidase I to the Ala-Cys-1 bond is restricted. This is simply an issue of yield from an enzymatic reaction and does not diminish the significance of our findings regarding the recovery of MMP activity. As noted under "Results," processing of upwards of 95% of the amino-terminal appended Ala residue could be obtained under more exhaustive digestion conditions. Compared with the ragged amino-terminal processing of the wt TIMP-2, in which 75% of the correctly refolded material has the correct amino terminus, the production and subsequent aminopeptidase processing of AlaϩTIMP-2 may offer an alternative method for preparation of correctly folded, fully functional wt TIMP-2. The ability of AlaϩTIMP-2 to form a hydrodynamically stable complex with MMP-2 confirms the concept that TIMP-2 interacts with at least two sites on the MMP-2 molecule: the four-bladed propeller structure of the carboxylterminal hemopexin-like domain and the active site. Furthermore, the ability of AlaϩTIMP-2 to form a stable complex is consistent with the finding that the carboxyl-terminal domain interactions between MMP-2 and TIMP-2 are the predominant high affinity interaction (29) . It is interesting to note that incubation of active MMP-2 with AlaϩTIMP-2, shown to form a complex that is stable upon gel filtration chromatography, still retains significant proteolytic activity in the thiopeptolide assay. This suggests that the TIMP-2 binding site in the carboxyl-terminal hemopexin-like domain must be sufficiently isolated from the MMP-2 active site such that there is no detectable alteration in proteolytic activity upon binding the 21-kDa TIMP-2 molecule. This is also consistent with the finding that AlaϩTIMP-2 shows no significant detectable inhibitory activity in the zymogram (Fig. 4B,  upper panel) . These observations suggest that the binding of TIMP-2 to the carboxyl-terminal, hemopexin domain does not alter significantly decrease interaction with either macromolecular (gelatin) or peptide substrates.
The AlaϩTIMP-2 protein provides an excellent tool for specifically determining the role of MMP inhibitory activity against a background of the other putative biological functions of TIMP-2. To this end, the requirement for MMP inhibitor activity in TIMP-2-mediated growth effects was tested utilizing AlaϩTIMP-2 protein. These results demonstrate that, like wt TIMP-2, AlaϩTIMP-2 stimulated growth of quiescent fibroblast and blunted the response of these cells to the effects of bFGF. This is definitive proof that TIMPs possess biological activities, such as growth modulation, that are completely independent of MMP inhibitor activity. Recently we have demonstrated that TIMP-1, but not TIMP-2, can prevent the programmed cell death of neoplastic lymphoid B cells in vitro and may function as a B cell differentiation factor (30, 31) . Future experiments will prepare similar Alaϩ mutants of TIMP-1, TIMP-3, and TIMP-4. These reagents should prove useful in analysis of novel biological activities of these TIMPs. These experiments should definitively demonstrate the often compounding influence of MMP inhibitory activity in the putative growth effects of TIMPs on a variety of cell types.
